{"id":49127,"date":"2025-11-27T16:22:09","date_gmt":"2025-11-27T08:22:09","guid":{"rendered":"https:\/\/flcube.com\/?p=49127"},"modified":"2026-04-28T12:37:47","modified_gmt":"2026-04-28T04:37:47","slug":"beones-sotoclax-wins-fda-priority-review-for-mantle-cell-lymphoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49127","title":{"rendered":"BeOne&#8217;s Sotoclax Wins FDA Priority Review for Mantle Cell Lymphoma"},"content":{"rendered":"\n<p><strong>BeOne Medicines Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ONC:NASDAQ\">NASDAQ: ONC<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/6160:HKG\">HKG:\u202f6160<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688235:SHA\">SHA:\u202f688235<\/a>) announced that the <strong>U.S. FDA<\/strong> has accepted its New Drug Application (NDA) for <strong>Sotoclax<\/strong>, a next\u2011generation BCL2 inhibitor, and granted <strong>Priority Review designation<\/strong> for the treatment of <strong>relapsed or refractory (R\/R) Mantle Cell Lymphoma (MCL)<\/strong> in patients previously treated with BTK inhibitors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Sotoclax (next\u2011generation BCL2 inhibitor)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>BeOne Medicines Ltd. (ONC; 6160; 688235)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Application Type<\/strong><\/td><td>New Drug Application (NDA) with Priority Review<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>R\/R MCL post BTK inhibitor therapy<\/td><\/tr><tr><td><strong>Study Basis<\/strong><\/td><td>BGB\u201111417\u2011201 (NCT05471843), global Phase\u202f1\/2<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Overall Response Rate (ORR) \u2013 met<\/td><\/tr><tr><td><strong>Key Secondary Endpoints<\/strong><\/td><td>CR rate, DOR, PFS \u2013 positive results<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Well\u2011tolerated, manageable<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>FDA review; Project Orbis participation; EMA submission planned<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-bgb-11417-201-study\">Clinical Evidence \u2013 BGB\u201111417\u2011201 Study<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Overall Response Rate (ORR)<\/strong><\/td><td>Clinically meaningful responses in heavily pre\u2011treated population<\/td><\/tr><tr><td><strong>Complete Response (CR) Rate<\/strong><\/td><td>Positive results reported<\/td><\/tr><tr><td><strong>Duration of Response (DOR)<\/strong><\/td><td>Positive results reported<\/td><\/tr><tr><td><strong>Progression\u2011Free Survival (PFS)<\/strong><\/td><td>Positive results reported<\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>No DLTs; manageable adverse events<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-initiatives\">Strategic Initiatives<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Project Orbis:<\/strong> BeOne will participate in FDA\u2019s Project Orbis framework for cooperative oncology review with international regulators<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> Plans to submit Phase\u202f1\/2 data to <strong>EMA<\/strong> and other regulatory bodies to expedite approvals in more countries<\/li>\n\n\n\n<li><strong>Market Access:<\/strong> Priority Review designation shortens FDA review timeline from 10 to 6 months<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>U.S. R\/R MCL Patient Pool<\/strong><\/td><td>~3,500 patients annually<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>BTK inhibitors (ibrutinib, acalabrutinib); limited options post\u2011BTK failure<\/td><\/tr><tr><td><strong>BCL2 Inhibitor Market<\/strong><\/td><td>$2.5\u202fbillion globally (2024); expanding in hematology<\/td><\/tr><tr><td><strong>Pricing<\/strong><\/td><td>Expected $150,000\u2011200,000\/year (aligns with oral oncolytics)<\/td><\/tr><tr><td><strong>Peak Sales Forecast<\/strong><\/td><td><strong>$300\u2011450\u202fmillion<\/strong> (U.S. peak) by 2031<\/td><\/tr><tr><td><strong>Competitive Landscape:<\/strong> <strong>AbbVie\/Roche\u2019s Venclexta<\/strong> approved in CLL\/SLL but not MCL; Sotoclax could be <strong>first BCL2 inhibitor in MCL<\/strong><\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Sotoclax\u2019s regulatory review, commercial potential, and global expansion plans. Actual results may differ materially due to risks including FDA approval outcomes, competitive responses, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA:\u202f688235) announced that the U.S. FDA has accepted its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49129,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2092,16,847,38,3046,848],"class_list":["post-49127","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-beone-medicines","tag-cancer","tag-hkg-6160","tag-market-approval-filings","tag-nasdaq-onc","tag-sha-688235"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BeOne&#039;s Sotoclax Wins FDA Priority Review for Mantle Cell Lymphoma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA:\u202f688235) announced that the U.S. FDA has accepted its New Drug Application (NDA) for Sotoclax, a next\u2011generation BCL2 inhibitor, and granted Priority Review designation for the treatment of relapsed or refractory (R\/R) Mantle Cell Lymphoma (MCL) in patients previously treated with BTK inhibitors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49127\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeOne&#039;s Sotoclax Wins FDA Priority Review for Mantle Cell Lymphoma\" \/>\n<meta property=\"og:description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA:\u202f688235) announced that the U.S. FDA has accepted its New Drug Application (NDA) for Sotoclax, a next\u2011generation BCL2 inhibitor, and granted Priority Review designation for the treatment of relapsed or refractory (R\/R) Mantle Cell Lymphoma (MCL) in patients previously treated with BTK inhibitors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49127\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-27T08:22:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-28T04:37:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2805.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49127#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49127\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeOne&#8217;s Sotoclax Wins FDA Priority Review for Mantle Cell Lymphoma\",\"datePublished\":\"2025-11-27T08:22:09+00:00\",\"dateModified\":\"2026-04-28T04:37:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49127\"},\"wordCount\":348,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49127#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2805.webp\",\"keywords\":[\"BeOne Medicines\",\"Cancer\",\"HKG: 6160\",\"Market approval filings\",\"NASDAQ: ONC\",\"SHA: 688235\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49127#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49127\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49127\",\"name\":\"BeOne's Sotoclax Wins FDA Priority Review for Mantle Cell Lymphoma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49127#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49127#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2805.webp\",\"datePublished\":\"2025-11-27T08:22:09+00:00\",\"dateModified\":\"2026-04-28T04:37:47+00:00\",\"description\":\"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA:\u202f688235) announced that the U.S. FDA has accepted its New Drug Application (NDA) for Sotoclax, a next\u2011generation BCL2 inhibitor, and granted Priority Review designation for the treatment of relapsed or refractory (R\\\/R) Mantle Cell Lymphoma (MCL) in patients previously treated with BTK inhibitors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49127#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49127\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49127#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2805.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2805.webp\",\"width\":1080,\"height\":608,\"caption\":\"BeOne's Sotoclax Wins FDA Priority Review for Mantle Cell Lymphoma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49127#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeOne&#8217;s Sotoclax Wins FDA Priority Review for Mantle Cell Lymphoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeOne's Sotoclax Wins FDA Priority Review for Mantle Cell Lymphoma - Insight, China&#039;s Pharmaceutical Industry","description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA:\u202f688235) announced that the U.S. FDA has accepted its New Drug Application (NDA) for Sotoclax, a next\u2011generation BCL2 inhibitor, and granted Priority Review designation for the treatment of relapsed or refractory (R\/R) Mantle Cell Lymphoma (MCL) in patients previously treated with BTK inhibitors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49127","og_locale":"en_US","og_type":"article","og_title":"BeOne's Sotoclax Wins FDA Priority Review for Mantle Cell Lymphoma","og_description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA:\u202f688235) announced that the U.S. FDA has accepted its New Drug Application (NDA) for Sotoclax, a next\u2011generation BCL2 inhibitor, and granted Priority Review designation for the treatment of relapsed or refractory (R\/R) Mantle Cell Lymphoma (MCL) in patients previously treated with BTK inhibitors.","og_url":"https:\/\/flcube.com\/?p=49127","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-27T08:22:09+00:00","article_modified_time":"2026-04-28T04:37:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2805.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49127#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49127"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeOne&#8217;s Sotoclax Wins FDA Priority Review for Mantle Cell Lymphoma","datePublished":"2025-11-27T08:22:09+00:00","dateModified":"2026-04-28T04:37:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49127"},"wordCount":348,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49127#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2805.webp","keywords":["BeOne Medicines","Cancer","HKG: 6160","Market approval filings","NASDAQ: ONC","SHA: 688235"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49127#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49127","url":"https:\/\/flcube.com\/?p=49127","name":"BeOne's Sotoclax Wins FDA Priority Review for Mantle Cell Lymphoma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49127#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49127#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2805.webp","datePublished":"2025-11-27T08:22:09+00:00","dateModified":"2026-04-28T04:37:47+00:00","description":"BeOne Medicines Ltd. (NASDAQ: ONC, HKG:\u202f6160, SHA:\u202f688235) announced that the U.S. FDA has accepted its New Drug Application (NDA) for Sotoclax, a next\u2011generation BCL2 inhibitor, and granted Priority Review designation for the treatment of relapsed or refractory (R\/R) Mantle Cell Lymphoma (MCL) in patients previously treated with BTK inhibitors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49127#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49127"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49127#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2805.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2805.webp","width":1080,"height":608,"caption":"BeOne's Sotoclax Wins FDA Priority Review for Mantle Cell Lymphoma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49127#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeOne&#8217;s Sotoclax Wins FDA Priority Review for Mantle Cell Lymphoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2805.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49127"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49127\/revisions"}],"predecessor-version":[{"id":49130,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49127\/revisions\/49130"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49129"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}